Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics.
Listeria monocytogenes is a facultative intracellular gram-positive bacterium that naturally infects professional antigen presenting cells (APC) to target antigens to both class I and class II antigen processing pathways. This infection process results in the stimulation of strong innate and adaptive immune responses, which make it an ideal candidate for a vaccine vector to deliver heterologous antigens. This ability of L. monocytogenes has been exploited by several researchers over the past decade to specifically deliver tumor-associated antigens that are poorly immunogenic such as self-antigens. This review describes the preclinical studies that have elucidated the multiple immune responses elicited by this bacterium that direct its ability to influence tumor growth.
Wallecha
Anu
A
Department of Antibody Technology ImClone Systems, a wholly-owned subsidiary of Eli Lilly & Co. New York, NY 10014, USA.
Carroll
Kyla Driscoll
KD
Maciag
Paulo Cesar
PC
Rivera
Sandra
S
Shahabi
Vafa
V
Paterson
Yvonne
Y
D000938:Antigen-Presenting Cells / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D008089:Listeria monocytogenes / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D008088:Listeriosis / Q000276:immunology* / Q000382:microbiology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use*; D014774:Virulence; D037521:Virulence Factors / Q000235:genetics / Q000276:immunology
D019496:Cancer Vaccines; D014614:Vaccines, Synthetic; D037521:Virulence Factors